Comparative Benchmarking
In the context of the broader market, INDP competes directly with industry leaders such as AIM and SLXN. With a market capitalization of $3.99M, it holds a significant position in the sector. When comparing efficiency, INDP's gross margin of N/A stands against AIM's -90.48% and SLXN's N/A. Such benchmarking helps identify whether Indaptus Therapeutics Inc is trading at a premium or discount relative to its financial performance.
